| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 102 | 2024 | 2600 | 11.810 |
Why?
|
| Lung Diseases, Interstitial | 37 | 2024 | 235 | 10.410 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 25 | 2024 | 165 | 8.410 |
Why?
|
| Lung | 40 | 2024 | 1170 | 4.850 |
Why?
|
| Radiography, Thoracic | 21 | 2020 | 320 | 3.730 |
Why?
|
| Alveolitis, Extrinsic Allergic | 8 | 2024 | 34 | 3.350 |
Why?
|
| Lung Neoplasms | 27 | 2024 | 2261 | 3.290 |
Why?
|
| Lung Diseases | 11 | 2023 | 263 | 2.510 |
Why?
|
| Pulmonary Fibrosis | 10 | 2023 | 123 | 2.460 |
Why?
|
| Diagnostic Imaging | 16 | 2023 | 469 | 2.310 |
Why?
|
| Humans | 210 | 2024 | 86601 | 2.120 |
Why?
|
| Lymph Nodes | 7 | 2019 | 530 | 2.020 |
Why?
|
| Diagnosis, Differential | 33 | 2020 | 1565 | 1.980 |
Why?
|
| Radiology | 12 | 2022 | 194 | 1.960 |
Why?
|
| Solitary Pulmonary Nodule | 6 | 2022 | 138 | 1.660 |
Why?
|
| Computed Tomography Angiography | 9 | 2020 | 131 | 1.590 |
Why?
|
| Connective Tissue Diseases | 5 | 2021 | 67 | 1.570 |
Why?
|
| Middle Aged | 84 | 2021 | 25017 | 1.510 |
Why?
|
| Idiopathic Interstitial Pneumonias | 9 | 2019 | 28 | 1.480 |
Why?
|
| Urinary Bladder Neoplasms | 9 | 2021 | 382 | 1.480 |
Why?
|
| Multiple Pulmonary Nodules | 4 | 2024 | 9 | 1.470 |
Why?
|
| Dyspnea | 5 | 2020 | 73 | 1.410 |
Why?
|
| Incidental Findings | 5 | 2018 | 95 | 1.400 |
Why?
|
| Aged | 66 | 2023 | 18402 | 1.390 |
Why?
|
| Utilization Review | 2 | 2019 | 21 | 1.340 |
Why?
|
| Societies, Medical | 18 | 2023 | 572 | 1.310 |
Why?
|
| Pulmonologists | 2 | 2018 | 6 | 1.300 |
Why?
|
| Male | 92 | 2023 | 40956 | 1.290 |
Why?
|
| Circulating Tumor DNA | 4 | 2022 | 37 | 1.270 |
Why?
|
| Female | 92 | 2023 | 44507 | 1.260 |
Why?
|
| Coronary Artery Disease | 8 | 2020 | 350 | 1.230 |
Why?
|
| Practice Guidelines as Topic | 11 | 2020 | 1034 | 1.210 |
Why?
|
| Thoracic Injuries | 6 | 2020 | 32 | 1.200 |
Why?
|
| Radiology Department, Hospital | 2 | 2018 | 27 | 1.180 |
Why?
|
| Wounds, Nonpenetrating | 4 | 2020 | 92 | 1.170 |
Why?
|
| Cough | 3 | 2020 | 54 | 1.160 |
Why?
|
| Interdisciplinary Communication | 2 | 2018 | 130 | 1.140 |
Why?
|
| Aortic Diseases | 3 | 2019 | 100 | 1.110 |
Why?
|
| Diagnostic Errors | 2 | 2018 | 160 | 1.100 |
Why?
|
| Aorta, Thoracic | 3 | 2019 | 165 | 1.090 |
Why?
|
| Biopsy | 9 | 2021 | 1161 | 1.080 |
Why?
|
| Occupational Exposure | 2 | 2023 | 80 | 1.060 |
Why?
|
| Occupational Diseases | 3 | 2023 | 55 | 1.050 |
Why?
|
| Genomics | 12 | 2021 | 720 | 1.010 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2021 | 3352 | 1.000 |
Why?
|
| Radiologists | 4 | 2023 | 46 | 0.960 |
Why?
|
| Retrospective Studies | 31 | 2024 | 8475 | 0.950 |
Why?
|
| Pneumoconiosis | 1 | 2023 | 5 | 0.950 |
Why?
|
| Scleroderma, Systemic | 3 | 2020 | 43 | 0.930 |
Why?
|
| Sensitivity and Specificity | 14 | 2021 | 1990 | 0.930 |
Why?
|
| BRCA2 Protein | 3 | 2021 | 158 | 0.920 |
Why?
|
| Reproducibility of Results | 13 | 2021 | 2705 | 0.890 |
Why?
|
| Teleradiology | 1 | 2022 | 4 | 0.880 |
Why?
|
| Mediastinum | 3 | 2019 | 46 | 0.880 |
Why?
|
| Contrast Media | 14 | 2019 | 1077 | 0.880 |
Why?
|
| Mucin-5B | 3 | 2019 | 11 | 0.870 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2019 | 185 | 0.850 |
Why?
|
| Carcinoma, Transitional Cell | 6 | 2020 | 164 | 0.840 |
Why?
|
| Coronary Angiography | 9 | 2019 | 232 | 0.810 |
Why?
|
| Peer Review | 2 | 2023 | 24 | 0.800 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2022 | 1074 | 0.800 |
Why?
|
| Radiology Information Systems | 3 | 2018 | 76 | 0.800 |
Why?
|
| Phthalazines | 2 | 2018 | 39 | 0.790 |
Why?
|
| Psoriasis | 6 | 2020 | 240 | 0.780 |
Why?
|
| Pleura | 3 | 2020 | 30 | 0.780 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2018 | 72 | 0.780 |
Why?
|
| Sarcoidosis, Pulmonary | 3 | 2019 | 17 | 0.770 |
Why?
|
| Pulmonary Embolism | 3 | 2020 | 221 | 0.770 |
Why?
|
| Positron Emission Tomography Computed Tomography | 7 | 2021 | 86 | 0.770 |
Why?
|
| Fluorodeoxyglucose F18 | 9 | 2018 | 138 | 0.760 |
Why?
|
| Survival Analysis | 5 | 2018 | 1538 | 0.750 |
Why?
|
| Pulmonary Artery | 4 | 2019 | 305 | 0.750 |
Why?
|
| Piperazines | 3 | 2020 | 272 | 0.750 |
Why?
|
| Lymphatic Metastasis | 5 | 2019 | 481 | 0.750 |
Why?
|
| Predictive Value of Tests | 7 | 2021 | 1673 | 0.740 |
Why?
|
| B7-H1 Antigen | 2 | 2021 | 250 | 0.730 |
Why?
|
| Early Detection of Cancer | 3 | 2018 | 392 | 0.720 |
Why?
|
| Adult | 50 | 2023 | 25640 | 0.720 |
Why?
|
| Quality Assurance, Health Care | 2 | 2018 | 220 | 0.710 |
Why?
|
| Cohort Studies | 15 | 2023 | 2767 | 0.710 |
Why?
|
| Radiopharmaceuticals | 8 | 2018 | 179 | 0.710 |
Why?
|
| Cysts | 3 | 2023 | 104 | 0.700 |
Why?
|
| Pleural Diseases | 2 | 2016 | 13 | 0.680 |
Why?
|
| Granuloma | 3 | 2016 | 65 | 0.680 |
Why?
|
| Positron-Emission Tomography | 6 | 2016 | 329 | 0.670 |
Why?
|
| Pulmonary Alveoli | 2 | 2016 | 71 | 0.660 |
Why?
|
| Pneumonia, Bacterial | 2 | 2016 | 28 | 0.650 |
Why?
|
| Allied Health Personnel | 1 | 2018 | 19 | 0.640 |
Why?
|
| Autoimmune Diseases | 2 | 2017 | 241 | 0.630 |
Why?
|
| Urothelium | 1 | 2018 | 70 | 0.630 |
Why?
|
| Fibrosis | 7 | 2024 | 203 | 0.620 |
Why?
|
| Technology, Radiologic | 1 | 2018 | 103 | 0.610 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 1464 | 0.610 |
Why?
|
| Feedback | 1 | 2018 | 133 | 0.610 |
Why?
|
| Prognosis | 15 | 2021 | 3674 | 0.610 |
Why?
|
| United States | 26 | 2023 | 6665 | 0.610 |
Why?
|
| Gadolinium | 3 | 2014 | 103 | 0.600 |
Why?
|
| Evidence-Based Medicine | 13 | 2021 | 429 | 0.590 |
Why?
|
| Physician Incentive Plans | 1 | 2016 | 21 | 0.590 |
Why?
|
| Efficiency | 1 | 2016 | 40 | 0.580 |
Why?
|
| Speech Recognition Software | 1 | 2016 | 5 | 0.580 |
Why?
|
| Prevalence | 8 | 2021 | 1239 | 0.580 |
Why?
|
| Medical Audit | 1 | 2016 | 41 | 0.570 |
Why?
|
| Tracheomalacia | 1 | 2016 | 2 | 0.560 |
Why?
|
| Medical Records | 1 | 2016 | 119 | 0.560 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2016 | 5 | 0.560 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2016 | 31 | 0.550 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2013 | 159 | 0.550 |
Why?
|
| Breast Implants | 1 | 2015 | 23 | 0.530 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2020 | 128 | 0.530 |
Why?
|
| Gases | 1 | 2015 | 30 | 0.530 |
Why?
|
| Birt-Hogg-Dube Syndrome | 2 | 2014 | 3 | 0.530 |
Why?
|
| Calcinosis | 1 | 2016 | 224 | 0.520 |
Why?
|
| Lymphangioleiomyomatosis | 2 | 2014 | 8 | 0.520 |
Why?
|
| Cryptogenic Organizing Pneumonia | 2 | 2012 | 5 | 0.520 |
Why?
|
| Mutation | 11 | 2022 | 3967 | 0.520 |
Why?
|
| Academic Medical Centers | 2 | 2018 | 379 | 0.520 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2014 | 19 | 0.520 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2021 | 930 | 0.510 |
Why?
|
| Tracheal Diseases | 2 | 2013 | 13 | 0.510 |
Why?
|
| Lung Transplantation | 2 | 2018 | 175 | 0.510 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 484 | 0.510 |
Why?
|
| Faculty, Medical | 1 | 2016 | 178 | 0.500 |
Why?
|
| Carcinoma | 1 | 2018 | 436 | 0.500 |
Why?
|
| Lymphatic Diseases | 1 | 2014 | 37 | 0.490 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2014 | 19 | 0.480 |
Why?
|
| Motivation | 1 | 2016 | 287 | 0.480 |
Why?
|
| Chronic Disease | 7 | 2020 | 970 | 0.480 |
Why?
|
| Cyclin-Dependent Kinase 2 | 2 | 2011 | 25 | 0.480 |
Why?
|
| Pulmonary Valve | 2 | 2020 | 32 | 0.470 |
Why?
|
| Sarcoidosis | 1 | 2014 | 71 | 0.470 |
Why?
|
| Testicular Neoplasms | 3 | 2019 | 105 | 0.470 |
Why?
|
| Disease Progression | 7 | 2021 | 1531 | 0.460 |
Why?
|
| Aorta | 3 | 2020 | 280 | 0.450 |
Why?
|
| Mass Screening | 1 | 2017 | 617 | 0.450 |
Why?
|
| Pulmonary Circulation | 2 | 2012 | 85 | 0.450 |
Why?
|
| Ventricular Septum | 1 | 2012 | 11 | 0.450 |
Why?
|
| Image Enhancement | 2 | 2013 | 563 | 0.440 |
Why?
|
| Pulmonary Subvalvular Stenosis | 1 | 2012 | 1 | 0.440 |
Why?
|
| Cystectomy | 5 | 2021 | 101 | 0.440 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2021 | 166 | 0.440 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2012 | 67 | 0.430 |
Why?
|
| Echocardiography | 4 | 2020 | 911 | 0.430 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2020 | 1075 | 0.430 |
Why?
|
| Systole | 1 | 2012 | 129 | 0.430 |
Why?
|
| Myocardial Ischemia | 1 | 2013 | 162 | 0.420 |
Why?
|
| Aneurysm | 1 | 2012 | 58 | 0.420 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2011 | 5 | 0.420 |
Why?
|
| Smoking | 3 | 2017 | 609 | 0.410 |
Why?
|
| Lymphadenopathy | 2 | 2021 | 16 | 0.400 |
Why?
|
| Kidney Neoplasms | 4 | 2021 | 621 | 0.400 |
Why?
|
| Pulmonary Infarction | 1 | 2010 | 1 | 0.390 |
Why?
|
| Immunocompromised Host | 3 | 2019 | 140 | 0.390 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 316 | 0.380 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 301 | 0.380 |
Why?
|
| Inhalation Exposure | 2 | 2021 | 28 | 0.380 |
Why?
|
| Pulmonary Emphysema | 2 | 2023 | 30 | 0.380 |
Why?
|
| Lung Diseases, Fungal | 1 | 2010 | 17 | 0.380 |
Why?
|
| Hematoma | 1 | 2011 | 104 | 0.380 |
Why?
|
| Mucormycosis | 1 | 2010 | 14 | 0.380 |
Why?
|
| Mitral Valve | 1 | 2012 | 248 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 4 | 2020 | 266 | 0.370 |
Why?
|
| G2 Phase | 1 | 2010 | 34 | 0.370 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2020 | 456 | 0.370 |
Why?
|
| Phenotype | 7 | 2019 | 2377 | 0.370 |
Why?
|
| Antineoplastic Agents | 6 | 2019 | 2357 | 0.360 |
Why?
|
| Graft Rejection | 1 | 2016 | 1065 | 0.360 |
Why?
|
| Observer Variation | 4 | 2020 | 602 | 0.350 |
Why?
|
| Pulmonary Alveolar Proteinosis | 1 | 2009 | 4 | 0.350 |
Why?
|
| Heart Diseases | 1 | 2012 | 290 | 0.350 |
Why?
|
| Mitosis | 1 | 2010 | 153 | 0.350 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2019 | 54 | 0.350 |
Why?
|
| Emphysema | 2 | 2023 | 22 | 0.350 |
Why?
|
| Adenocarcinoma | 4 | 2020 | 1169 | 0.340 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 381 | 0.340 |
Why?
|
| Aged, 80 and over | 13 | 2021 | 6501 | 0.340 |
Why?
|
| Amyloidosis | 1 | 2010 | 115 | 0.340 |
Why?
|
| Radiographic Image Enhancement | 4 | 2016 | 462 | 0.340 |
Why?
|
| Colorado | 3 | 2019 | 35 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2436 | 0.340 |
Why?
|
| Betacoronavirus | 3 | 2020 | 258 | 0.330 |
Why?
|
| Receptor, ErbB-2 | 3 | 2020 | 223 | 0.330 |
Why?
|
| DNA, Neoplasm | 2 | 2020 | 265 | 0.330 |
Why?
|
| Inflammation | 3 | 2018 | 920 | 0.320 |
Why?
|
| Asthma | 1 | 2016 | 955 | 0.310 |
Why?
|
| Neoplasm Invasiveness | 5 | 2021 | 552 | 0.310 |
Why?
|
| Heart Defects, Congenital | 2 | 2018 | 351 | 0.300 |
Why?
|
| Feasibility Studies | 4 | 2022 | 751 | 0.300 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2021 | 426 | 0.300 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 232 | 0.300 |
Why?
|
| Respiratory Tract Infections | 3 | 2019 | 105 | 0.300 |
Why?
|
| Gene Expression Profiling | 4 | 2021 | 1384 | 0.300 |
Why?
|
| Respiratory Tract Diseases | 2 | 2018 | 45 | 0.300 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2019 | 108 | 0.290 |
Why?
|
| Gene Rearrangement | 4 | 2020 | 170 | 0.290 |
Why?
|
| Genotype | 4 | 2017 | 1850 | 0.290 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2019 | 427 | 0.290 |
Why?
|
| Respiratory-Gated Imaging Techniques | 2 | 2016 | 3 | 0.280 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 999 | 0.280 |
Why?
|
| Algorithms | 7 | 2019 | 1830 | 0.270 |
Why?
|
| Hematologic Neoplasms | 1 | 2009 | 329 | 0.270 |
Why?
|
| Cardiovascular Diseases | 3 | 2018 | 827 | 0.270 |
Why?
|
| DiGeorge Syndrome | 2 | 2017 | 14 | 0.270 |
Why?
|
| Atherosclerosis | 2 | 2018 | 243 | 0.260 |
Why?
|
| Anthracosis | 2 | 2022 | 2 | 0.250 |
Why?
|
| Rheumatoid Factor | 2 | 2021 | 24 | 0.250 |
Why?
|
| Neoplasm Staging | 7 | 2021 | 1937 | 0.240 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 735 | 0.240 |
Why?
|
| Risk Factors | 10 | 2021 | 5416 | 0.240 |
Why?
|
| Treatment Outcome | 10 | 2020 | 7988 | 0.240 |
Why?
|
| Prospective Studies | 10 | 2023 | 4210 | 0.240 |
Why?
|
| Thoracic Wall | 2 | 2021 | 21 | 0.240 |
Why?
|
| Angiography | 3 | 2014 | 208 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 1197 | 0.230 |
Why?
|
| Hypertension, Pulmonary | 3 | 2018 | 345 | 0.230 |
Why?
|
| Thyroid Nodule | 1 | 2024 | 51 | 0.230 |
Why?
|
| Carcinoma, Bronchogenic | 2 | 2013 | 30 | 0.230 |
Why?
|
| Stroke | 1 | 2012 | 965 | 0.220 |
Why?
|
| Biological Specimen Banks | 2 | 2020 | 65 | 0.220 |
Why?
|
| Hemoptysis | 2 | 2014 | 24 | 0.220 |
Why?
|
| Software | 3 | 2018 | 654 | 0.220 |
Why?
|
| Pancreatic Neoplasms | 2 | 2019 | 645 | 0.220 |
Why?
|
| Multidetector Computed Tomography | 3 | 2019 | 54 | 0.210 |
Why?
|
| Genetic Variation | 2 | 2019 | 1351 | 0.210 |
Why?
|
| Serologic Tests | 2 | 2020 | 41 | 0.210 |
Why?
|
| Medical History Taking | 2 | 2020 | 80 | 0.210 |
Why?
|
| Mediastinal Diseases | 1 | 2021 | 21 | 0.210 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2019 | 47 | 0.200 |
Why?
|
| Urethral Neoplasms | 1 | 2021 | 10 | 0.200 |
Why?
|
| Carcinoma, Medullary | 1 | 2021 | 11 | 0.200 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 49 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 592 | 0.200 |
Why?
|
| Myocardial Contusions | 1 | 2020 | 1 | 0.200 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 2887 | 0.200 |
Why?
|
| Nuclear Proteins | 2 | 2019 | 696 | 0.200 |
Why?
|
| Oncogene Fusion | 1 | 2020 | 8 | 0.200 |
Why?
|
| Atrial Septum | 2 | 2010 | 9 | 0.190 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2016 | 579 | 0.190 |
Why?
|
| Occupational Health | 1 | 2021 | 32 | 0.190 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 2020 | 2 | 0.190 |
Why?
|
| Vaping | 1 | 2021 | 29 | 0.190 |
Why?
|
| Ureteral Neoplasms | 1 | 2020 | 13 | 0.190 |
Why?
|
| Urogenital Neoplasms | 1 | 2020 | 23 | 0.190 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 12 | 0.190 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2020 | 19 | 0.190 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2020 | 1 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 5 | 2021 | 317 | 0.190 |
Why?
|
| Gastropexy | 1 | 2020 | 1 | 0.190 |
Why?
|
| Acute Lung Injury | 1 | 2021 | 60 | 0.190 |
Why?
|
| Heart Septal Defects, Atrial | 2 | 2010 | 64 | 0.190 |
Why?
|
| Ossification, Heterotopic | 1 | 2020 | 31 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2021 | 2261 | 0.190 |
Why?
|
| Receptors, Androgen | 1 | 2021 | 113 | 0.190 |
Why?
|
| Registries | 3 | 2021 | 702 | 0.190 |
Why?
|
| Bronchiolitis | 3 | 2015 | 7 | 0.190 |
Why?
|
| Radiation Dosage | 2 | 2019 | 227 | 0.190 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2020 | 3 | 0.190 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 121 | 0.190 |
Why?
|
| Parenchymal Tissue | 1 | 2020 | 6 | 0.180 |
Why?
|
| Piperidines | 2 | 2018 | 181 | 0.180 |
Why?
|
| Survival Rate | 3 | 2019 | 1860 | 0.180 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 2356 | 0.180 |
Why?
|
| Genome | 2 | 2020 | 372 | 0.180 |
Why?
|
| Internship and Residency | 1 | 2009 | 1004 | 0.180 |
Why?
|
| Coronavirus | 1 | 2020 | 19 | 0.180 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 29 | 0.180 |
Why?
|
| Protein Kinases | 2 | 2011 | 209 | 0.180 |
Why?
|
| Pandemics | 3 | 2020 | 740 | 0.180 |
Why?
|
| Gastrostomy | 1 | 2020 | 69 | 0.180 |
Why?
|
| Translocation, Genetic | 1 | 2020 | 265 | 0.180 |
Why?
|
| Immunoglobulin A | 1 | 2019 | 80 | 0.180 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 121 | 0.180 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2019 | 43 | 0.180 |
Why?
|
| Autoimmunity | 2 | 2018 | 160 | 0.180 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 200 | 0.170 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2021 | 111 | 0.170 |
Why?
|
| Medicare Part B | 1 | 2019 | 3 | 0.170 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 42 | 0.170 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2019 | 18 | 0.170 |
Why?
|
| Referral and Consultation | 2 | 2019 | 326 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2021 | 268 | 0.170 |
Why?
|
| Urologic Neoplasms | 1 | 2020 | 77 | 0.170 |
Why?
|
| Artifacts | 3 | 2019 | 244 | 0.170 |
Why?
|
| Hematopoietic System | 1 | 2018 | 13 | 0.170 |
Why?
|
| Arthritis, Psoriatic | 1 | 2019 | 32 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 21 | 0.170 |
Why?
|
| Quinazolines | 2 | 2018 | 220 | 0.170 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2019 | 47 | 0.170 |
Why?
|
| Rheumatologists | 1 | 2018 | 6 | 0.170 |
Why?
|
| Mediastinal Neoplasms | 1 | 2019 | 46 | 0.170 |
Why?
|
| Seminoma | 1 | 2018 | 10 | 0.170 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2019 | 48 | 0.170 |
Why?
|
| Carcinoma, Large Cell | 1 | 2018 | 39 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 97 | 0.170 |
Why?
|
| Bronchoscopy | 5 | 2021 | 152 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2019 | 267 | 0.160 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2020 | 134 | 0.160 |
Why?
|
| Pathologists | 1 | 2018 | 24 | 0.160 |
Why?
|
| Parathyroid Neoplasms | 1 | 2018 | 55 | 0.160 |
Why?
|
| Statistics as Topic | 2 | 2017 | 238 | 0.160 |
Why?
|
| Comparative Effectiveness Research | 2 | 2016 | 53 | 0.160 |
Why?
|
| Lymphocytes | 1 | 2020 | 464 | 0.160 |
Why?
|
| Carbazoles | 1 | 2018 | 51 | 0.160 |
Why?
|
| Lipoproteins, HDL | 1 | 2018 | 96 | 0.160 |
Why?
|
| Drug Substitution | 1 | 2018 | 25 | 0.160 |
Why?
|
| Amygdala | 1 | 2018 | 84 | 0.160 |
Why?
|
| Cell Cycle Proteins | 2 | 2011 | 388 | 0.160 |
Why?
|
| Pneumonectomy | 1 | 2020 | 196 | 0.160 |
Why?
|
| Free Radical Scavengers | 1 | 2018 | 59 | 0.160 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 69 | 0.160 |
Why?
|
| Subcutaneous Fat | 1 | 2017 | 18 | 0.160 |
Why?
|
| Vasculitis | 1 | 2017 | 38 | 0.160 |
Why?
|
| Intra-Abdominal Fat | 1 | 2017 | 29 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 559 | 0.150 |
Why?
|
| Acetylcysteine | 1 | 2018 | 69 | 0.150 |
Why?
|
| Coronary Vessels | 1 | 2019 | 177 | 0.150 |
Why?
|
| Tetralogy of Fallot | 1 | 2017 | 44 | 0.150 |
Why?
|
| Adiposity | 1 | 2017 | 70 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2018 | 1804 | 0.150 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 3 | 2019 | 466 | 0.150 |
Why?
|
| Antirheumatic Agents | 1 | 2017 | 54 | 0.150 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 220 | 0.150 |
Why?
|
| Pathology, Clinical | 1 | 2017 | 33 | 0.150 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2016 | 23 | 0.150 |
Why?
|
| Transcriptome | 1 | 2021 | 580 | 0.150 |
Why?
|
| Machine Learning | 1 | 2019 | 232 | 0.150 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2016 | 18 | 0.150 |
Why?
|
| Consensus | 3 | 2024 | 335 | 0.150 |
Why?
|
| Biological Products | 1 | 2019 | 143 | 0.150 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 95 | 0.150 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2016 | 2 | 0.150 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2017 | 58 | 0.150 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2017 | 115 | 0.140 |
Why?
|
| Neutrophils | 1 | 2018 | 307 | 0.140 |
Why?
|
| Repressor Proteins | 1 | 2019 | 403 | 0.140 |
Why?
|
| Software Validation | 1 | 2016 | 3 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 937 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2017 | 348 | 0.140 |
Why?
|
| Mycobacterium avium Complex | 1 | 2016 | 6 | 0.140 |
Why?
|
| Azathioprine | 1 | 2016 | 125 | 0.140 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2018 | 206 | 0.140 |
Why?
|
| Myositis | 1 | 2016 | 17 | 0.140 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 153 | 0.140 |
Why?
|
| Time Factors | 6 | 2021 | 5209 | 0.140 |
Why?
|
| Atmospheric Pressure | 1 | 2015 | 2 | 0.140 |
Why?
|
| Stress, Psychological | 1 | 2018 | 313 | 0.130 |
Why?
|
| Hospitalization | 2 | 2018 | 848 | 0.130 |
Why?
|
| Altitude | 1 | 2015 | 40 | 0.130 |
Why?
|
| Neuroendocrine Cells | 1 | 2015 | 3 | 0.130 |
Why?
|
| Carrier Proteins | 1 | 2018 | 673 | 0.130 |
Why?
|
| Heart Ventricles | 1 | 2020 | 760 | 0.130 |
Why?
|
| Rib Fractures | 1 | 2014 | 8 | 0.130 |
Why?
|
| Cystic Fibrosis | 1 | 2016 | 112 | 0.130 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 111 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2016 | 223 | 0.130 |
Why?
|
| Heterozygote | 1 | 2016 | 365 | 0.130 |
Why?
|
| Pneumonia, Aspiration | 1 | 2014 | 19 | 0.130 |
Why?
|
| Acute Disease | 4 | 2019 | 826 | 0.130 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1019 | 0.130 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 288 | 0.120 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 247 | 0.120 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2014 | 25 | 0.120 |
Why?
|
| Biopsy, Needle | 2 | 2012 | 235 | 0.120 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 977 | 0.120 |
Why?
|
| Precision Medicine | 1 | 2018 | 395 | 0.120 |
Why?
|
| Glass | 1 | 2014 | 15 | 0.120 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2014 | 8 | 0.120 |
Why?
|
| Checkpoint Kinase 1 | 2 | 2011 | 13 | 0.120 |
Why?
|
| Young Adult | 6 | 2021 | 5974 | 0.120 |
Why?
|
| User-Computer Interface | 2 | 2012 | 185 | 0.120 |
Why?
|
| Bronchial Diseases | 1 | 2013 | 12 | 0.120 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2011 | 52 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2016 | 280 | 0.120 |
Why?
|
| Antibodies, Antinuclear | 3 | 2018 | 83 | 0.110 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 1801 | 0.110 |
Why?
|
| Comorbidity | 1 | 2017 | 943 | 0.110 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2014 | 101 | 0.110 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 1620 | 0.110 |
Why?
|
| Protons | 1 | 2013 | 98 | 0.110 |
Why?
|
| Ultrasonography | 3 | 2024 | 695 | 0.110 |
Why?
|
| Thorax | 1 | 2013 | 75 | 0.110 |
Why?
|
| Phantoms, Imaging | 2 | 2014 | 429 | 0.110 |
Why?
|
| Mediastinitis | 1 | 2012 | 14 | 0.110 |
Why?
|
| Cleft Palate | 1 | 2012 | 25 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 857 | 0.110 |
Why?
|
| Pulmonary Diffusing Capacity | 3 | 2017 | 24 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 744 | 0.110 |
Why?
|
| Dilatation, Pathologic | 1 | 2012 | 54 | 0.110 |
Why?
|
| Histoplasmosis | 1 | 2012 | 25 | 0.110 |
Why?
|
| Critical Care | 1 | 2015 | 370 | 0.110 |
Why?
|
| Chicago | 1 | 2017 | 1379 | 0.110 |
Why?
|
| Cardiac-Gated Imaging Techniques | 1 | 2012 | 19 | 0.110 |
Why?
|
| Alleles | 1 | 2016 | 1127 | 0.110 |
Why?
|
| Vital Capacity | 3 | 2017 | 64 | 0.110 |
Why?
|
| Pericarditis, Constrictive | 1 | 2012 | 5 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 1376 | 0.110 |
Why?
|
| Cardiac Tamponade | 1 | 2012 | 17 | 0.110 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2012 | 9 | 0.100 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2012 | 42 | 0.100 |
Why?
|
| Heart Septum | 1 | 2012 | 45 | 0.100 |
Why?
|
| Thoracic Diseases | 1 | 2012 | 25 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 819 | 0.100 |
Why?
|
| Atlases as Topic | 1 | 2011 | 7 | 0.100 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 1720 | 0.100 |
Why?
|
| T-Box Domain Proteins | 1 | 2012 | 118 | 0.100 |
Why?
|
| Tomography, Spiral Computed | 1 | 2011 | 76 | 0.100 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 294 | 0.100 |
Why?
|
| Bronchiectasis | 1 | 2010 | 13 | 0.100 |
Why?
|
| Adolescent | 5 | 2021 | 8979 | 0.100 |
Why?
|
| Cardiomyopathies | 1 | 2013 | 240 | 0.090 |
Why?
|
| Enzyme Stability | 1 | 2010 | 39 | 0.090 |
Why?
|
| cdc25 Phosphatases | 1 | 2010 | 18 | 0.090 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2012 | 187 | 0.090 |
Why?
|
| Hypotension | 1 | 2010 | 70 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2012 | 240 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 860 | 0.090 |
Why?
|
| Fever | 1 | 2010 | 125 | 0.090 |
Why?
|
| HCT116 Cells | 1 | 2010 | 151 | 0.090 |
Why?
|
| Bacteremia | 1 | 2010 | 99 | 0.090 |
Why?
|
| Trachea | 1 | 2011 | 293 | 0.090 |
Why?
|
| Logistic Models | 3 | 2018 | 1185 | 0.090 |
Why?
|
| Italy | 2 | 2021 | 106 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 3636 | 0.090 |
Why?
|
| Radiation, Ionizing | 1 | 2010 | 121 | 0.090 |
Why?
|
| Delphi Technique | 3 | 2014 | 80 | 0.090 |
Why?
|
| MCF-7 Cells | 2 | 2020 | 106 | 0.090 |
Why?
|
| Biomarkers | 3 | 2021 | 1718 | 0.090 |
Why?
|
| Washington | 1 | 2009 | 48 | 0.090 |
Why?
|
| Child | 4 | 2023 | 6926 | 0.090 |
Why?
|
| Cytoplasm | 1 | 2010 | 281 | 0.090 |
Why?
|
| Respiratory Function Tests | 2 | 2019 | 136 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 1621 | 0.080 |
Why?
|
| Professional Competence | 1 | 2009 | 68 | 0.080 |
Why?
|
| INDEL Mutation | 2 | 2018 | 30 | 0.080 |
Why?
|
| Palliative Care | 1 | 2010 | 257 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2010 | 692 | 0.080 |
Why?
|
| Protein Transport | 1 | 2010 | 411 | 0.080 |
Why?
|
| Chest Pain | 2 | 2021 | 42 | 0.080 |
Why?
|
| Liquid Biopsy | 2 | 2018 | 33 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 458 | 0.080 |
Why?
|
| Lung Injury | 2 | 2021 | 47 | 0.080 |
Why?
|
| HIV Infections | 1 | 2016 | 772 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2010 | 371 | 0.080 |
Why?
|
| Pyridines | 2 | 2020 | 309 | 0.080 |
Why?
|
| Cholesterol, HDL | 2 | 2018 | 165 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2020 | 2426 | 0.080 |
Why?
|
| Receptors, Estrogen | 2 | 2020 | 384 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2010 | 230 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2010 | 1106 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2011 | 556 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 526 | 0.070 |
Why?
|
| ErbB Receptors | 2 | 2020 | 485 | 0.070 |
Why?
|
| Animals | 4 | 2018 | 26581 | 0.070 |
Why?
|
| Patient Selection | 2 | 2020 | 685 | 0.070 |
Why?
|
| Mice | 3 | 2018 | 11352 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 746 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 878 | 0.070 |
Why?
|
| Forced Expiratory Volume | 2 | 2015 | 122 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2020 | 589 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2020 | 812 | 0.060 |
Why?
|
| Neoplasms | 1 | 2019 | 2897 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 2501 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 1204 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2021 | 3611 | 0.060 |
Why?
|
| ROC Curve | 2 | 2019 | 752 | 0.060 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 25 | 0.060 |
Why?
|
| Peer Group | 1 | 2023 | 72 | 0.060 |
Why?
|
| Iopamidol | 2 | 2013 | 10 | 0.060 |
Why?
|
| Radiography | 2 | 2016 | 813 | 0.060 |
Why?
|
| Models, Biological | 1 | 2010 | 1749 | 0.060 |
Why?
|
| Telomere | 1 | 2023 | 108 | 0.050 |
Why?
|
| Leukocytes | 1 | 2023 | 202 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2019 | 3241 | 0.050 |
Why?
|
| CD57 Antigens | 1 | 2021 | 5 | 0.050 |
Why?
|
| CD56 Antigen | 1 | 2021 | 18 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 137 | 0.050 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2021 | 27 | 0.050 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2020 | 23 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2020 | 106 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2020 | 38 | 0.050 |
Why?
|
| Psychotropic Drugs | 1 | 2021 | 75 | 0.050 |
Why?
|
| New York | 1 | 2020 | 69 | 0.050 |
Why?
|
| Nicotinic Agonists | 1 | 2021 | 72 | 0.050 |
Why?
|
| Cryosurgery | 1 | 2020 | 40 | 0.050 |
Why?
|
| Chromosomes, Human, X | 1 | 2020 | 55 | 0.050 |
Why?
|
| Dronabinol | 1 | 2021 | 53 | 0.050 |
Why?
|
| Muscles | 1 | 2021 | 194 | 0.050 |
Why?
|
| Ontario | 1 | 2020 | 52 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2022 | 302 | 0.050 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2021 | 50 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 125 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 2270 | 0.050 |
Why?
|
| Body Composition | 1 | 2020 | 68 | 0.050 |
Why?
|
| France | 1 | 2020 | 47 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2020 | 156 | 0.050 |
Why?
|
| North America | 1 | 2020 | 180 | 0.050 |
Why?
|
| Brazil | 1 | 2020 | 69 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2021 | 476 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2021 | 504 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 267 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 288 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 137 | 0.040 |
Why?
|
| Organ Size | 1 | 2020 | 364 | 0.040 |
Why?
|
| Nicotine | 1 | 2021 | 194 | 0.040 |
Why?
|
| Telomerase | 1 | 2019 | 55 | 0.040 |
Why?
|
| Genomic Structural Variation | 1 | 2019 | 3 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 65 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 62 | 0.040 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2018 | 3 | 0.040 |
Why?
|
| ras Guanine Nucleotide Exchange Factors | 1 | 2018 | 8 | 0.040 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2018 | 4 | 0.040 |
Why?
|
| Radiation Exposure | 1 | 2019 | 24 | 0.040 |
Why?
|
| Neurofibromin 1 | 1 | 2018 | 8 | 0.040 |
Why?
|
| Equipment Design | 1 | 2020 | 406 | 0.040 |
Why?
|
| Motion | 1 | 2019 | 85 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2018 | 105 | 0.040 |
Why?
|
| Necrosis | 1 | 2019 | 204 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 56 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 41 | 0.040 |
Why?
|
| Anilides | 1 | 2018 | 47 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2018 | 48 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2020 | 246 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 456 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 678 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2019 | 152 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 645 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 468 | 0.040 |
Why?
|
| Clinical Competence | 1 | 2023 | 751 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2018 | 131 | 0.040 |
Why?
|
| MEF2 Transcription Factors | 1 | 2017 | 9 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 273 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 285 | 0.040 |
Why?
|
| Propensity Score | 1 | 2018 | 136 | 0.040 |
Why?
|
| Loss of Heterozygosity | 1 | 2017 | 85 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2018 | 222 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 154 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 262 | 0.040 |
Why?
|
| Phototherapy | 1 | 2017 | 35 | 0.040 |
Why?
|
| Hospitals | 1 | 2020 | 294 | 0.040 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 171 | 0.040 |
Why?
|
| Gene Dosage | 1 | 2018 | 207 | 0.040 |
Why?
|
| Proteome | 1 | 2018 | 124 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 143 | 0.040 |
Why?
|
| Whole Body Imaging | 1 | 2017 | 41 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 109 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2015 | 1578 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2017 | 293 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 277 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2018 | 596 | 0.040 |
Why?
|
| Length of Stay | 1 | 2020 | 700 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 153 | 0.040 |
Why?
|
| Pneumocystis carinii | 1 | 2016 | 3 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 916 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2018 | 790 | 0.040 |
Why?
|
| Hypersplenism | 1 | 2016 | 2 | 0.040 |
Why?
|
| Risk | 1 | 2018 | 674 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 190 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2017 | 369 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 217 | 0.040 |
Why?
|
| Heart Rate | 1 | 2019 | 492 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 87 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2016 | 94 | 0.040 |
Why?
|
| Leukopenia | 1 | 2016 | 65 | 0.040 |
Why?
|
| Protein Domains | 1 | 2016 | 128 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 222 | 0.040 |
Why?
|
| Asbestosis | 1 | 2016 | 5 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 2016 | 52 | 0.040 |
Why?
|
| Arthritis | 1 | 2016 | 46 | 0.040 |
Why?
|
| Silicosis | 1 | 2016 | 2 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2017 | 250 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2020 | 374 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2017 | 473 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 1056 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 339 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2016 | 351 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 1204 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2019 | 1074 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2020 | 669 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 399 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2016 | 173 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2378 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 689 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 329 | 0.030 |
Why?
|
| Physical Examination | 1 | 2016 | 149 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2018 | 770 | 0.030 |
Why?
|
| Lung Abscess | 1 | 2014 | 5 | 0.030 |
Why?
|
| Infant | 1 | 2021 | 3045 | 0.030 |
Why?
|
| Chromatin | 1 | 2017 | 380 | 0.030 |
Why?
|
| Hyperplasia | 1 | 2015 | 148 | 0.030 |
Why?
|
| Multiple Trauma | 1 | 2014 | 34 | 0.030 |
Why?
|
| Diaphragm | 1 | 2014 | 50 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 2014 | 45 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1961 | 0.030 |
Why?
|
| Aortography | 1 | 2014 | 63 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2014 | 96 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 853 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2016 | 881 | 0.030 |
Why?
|
| Foreign Bodies | 1 | 2014 | 63 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 683 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 2468 | 0.030 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2013 | 13 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 138 | 0.030 |
Why?
|
| Bronchial Neoplasms | 1 | 2013 | 9 | 0.030 |
Why?
|
| Evidence-Based Dentistry | 1 | 2013 | 10 | 0.030 |
Why?
|
| Tracheal Neoplasms | 1 | 2013 | 8 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 2014 | 109 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 378 | 0.030 |
Why?
|
| Gene Order | 1 | 2012 | 22 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1753 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 2062 | 0.030 |
Why?
|
| Liver | 1 | 2017 | 1229 | 0.030 |
Why?
|
| Health Policy | 1 | 2014 | 180 | 0.030 |
Why?
|
| Inpatients | 1 | 2015 | 297 | 0.030 |
Why?
|
| Collagen Diseases | 1 | 2012 | 3 | 0.030 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2012 | 4 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2015 | 373 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2013 | 187 | 0.030 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2012 | 30 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 451 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2012 | 59 | 0.030 |
Why?
|
| Diastole | 1 | 2012 | 144 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 2013 | 291 | 0.030 |
Why?
|
| Embolization, Therapeutic | 1 | 2014 | 238 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 663 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 334 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2012 | 989 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2012 | 213 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2012 | 237 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2020 | 2207 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 1078 | 0.020 |
Why?
|
| Cell Survival | 1 | 2011 | 969 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 2330 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2010 | 478 | 0.020 |
Why?
|